Patents Assigned to Mineralys Therapeutics, Inc.
  • METHODS OF TREATING HYPERTENSION BY PERIODIC SUPPRESSION OF ALDOSTERONE SYNTHASE
    Publication number: 20250099475
    Abstract: This invention provides method of treating hypertension in a hypertensive subject, the method comprising administering to the subject a CYP 11?2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to inhibit 50% or more of CYP 11?2 beta hydroxylase's activity for 40-60% of a 24-hour period to thereby treat hypertension in the hypertensive subject.
    Type: Application
    Filed: January 19, 2023
    Publication date: March 27, 2025
    Applicants: Mineralys Therapeutics, Inc., Mitsubishi Tanabe Pharma Corporation
    Inventors: David Rodman, Brian Taylor Slingsby, Jon Congleton, Hidetoshi Shimizu, Yoshiyasu Ota, Madori Orihashi
  • SOLUBLE PHARMACEUTICAL COMPOSITIONS COMPRISING SALTS OF DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND
    Publication number: 20240366616
    Abstract: Disclosed are pharmaceutical compositions comprising a salt of a compound having the formula: and one or more excipients, wherein the pharmaceutical composition avoids inducing disproportionation of the salt of the compound.
    Type: Application
    Filed: July 20, 2022
    Publication date: November 7, 2024
    Applicants: Mineralys Therapeutics, Inc., Mitsubishi Tanabe Pharma Corporation
    Inventors: Robert McKean, Roch Thibert, Elizabeth Vadas, Yoshinori Ohashi, Fuminori Ozaki, Hiroki Ohshima, Hiroomi Nagata
  • CYP11B2 BETA HYDROXYLASE INHIBITORS FOR HYPERTENSION
    Publication number: 20240009201
    Abstract: The disclosure provides, inter alia, methods to treat hypertension in patients using CYP 11?2 beta hydroxylase inhibitors.
    Type: Application
    Filed: October 25, 2021
    Publication date: January 11, 2024
    Applicant: Mineralys Therapeutics, Inc.
    Inventors: Brian Taylor Slingsby, William Connolly Watt, David Rodman